| The 7th Annual China Pharmaceutical R&D Summit When: 8:30AM, Tuesday, April 24, 2012 - 5:30PM, Wednesday, April 25, 2012 Where: Grand Hyatt Shanghai Lecture Title : Advancing R&D through Innovation and Collaborations” Event Summary: The longest running R&D event in China, recognized and endorsed by top-level executives of the China’s pharma and biotech companies brings the knowledge, the network and the business partnering a notch higher. With proven attendance from top-level executives from China’s major pharma and biotech companies, 2012 promises over 400 relevant decision makers from Asia and internationally gathering to discuss innovation in Pharma R&D and emerging models of development. Hear from experts, meet potential collaborators and gather insights to re-align your very own R&D strategy – only at China Pharmaceutical R&D Summit. This is your best opportunity to spend three days learning from and networking with knowledgeable and experienced drug development experts. China Pharma R&D is a platform for pharma/biotech, investors, academics and other stakeholders in drug development in Asia to network and evaluate partnering opportunities in Asia. Speakers from Global Pharma: Dr Helmut Haning, SVP Head of Global Innovation Sourcing, Bayer Schering Pharma, Germany Ling Chen, Vice President of R&D China Operations, GlaxoSmithKline Kumar Penmetsa, Senior Director, Project Mgt & Strategic Operations, Bristol Myers Squibb, China Rong Chen, Head of Centre for Regulatory Excellence, GlaxoSmithKline, China Shirley Zhao, Managing Director, Genzyme, China Jennifer Hu, Vice President, Head of Innovation Center China, Global Drug Discovery, Bayer Healthcare Jun Bao, Director, Worldwide Business Development, Head of China, GlaxoSmithKline Dr Yuan Hua Ding, Senior Director and Head, External R&D Innovation Asia, Pfizer, USA Amy Jiang, Quality Operations Head, R&D China, Sanofi Aventis Fred Zheng, Clinical Biomarker Group, AstraZeneca Oncology Clinical Development, China Yuko Kikuchi, Clinical Regulatory, Strategy Planning & Management Section, Eisai, Japan Stella Xu, Executive Director, Roche Pharma Partnering, China Binhui (Ben ) Ni, Head of Scouting & Partnership, Sanofi Aventis, China Dr Donald R Russell, Senior Director, Global Clinical Operations, Eli Lilly & Company Dr Guenther Forster, Senior Vice President Medical Development & Strategies Emerging Markets, Merck Serono (confirming) Regional Thought Leaders: George Chen, Chief Medical Officer, BeiGene, China Herng-Der Chern, Distinguished Research Fellow, Center for Drug Evaluation, Taiwan Frank Shen, Vice President Global Data Management and Statistics, Global Pharmaceutical R&D, Abbott, USA May Tu, Clinical Franchise Head, Beijing Novartis Pharma Sofie Qiao, President and Co-Founder, Linq Pharmaceuticals, USA Dr Jingzong Qi, Vice President & Director of Clinical Research Center, FusoGen Pharmaceuticals, China Zhenping Zhu, President & CEO, Kadmon China Chia-Lin Wang, President, Development Center for Biotechnology, Taiwan James Yan, Executive Director, Hutchison Medipharma, China Helen Jiang, Vice President Clinical, Jiangsu Hengrui Medicine Company, China Allan Riting Liu, Vice President/Senior Advisor, Wanbang Biopharmaceutical Group, China Stephen Porter, CEO, VDDI Pharmaceuticals, CSO, Dragon Bioconsultants, Hong Kong Dr Satheeshkumar Sriharan, Chief Representative / Country Head- China, Dr.Reddy’s Laboratories, China Li Chen, President & CEO, Hua Medicine, China Dr Yuqiang Wang, CEO, Magpie Pharmaceuticals , Professor and Dean, Jinan University College of Pharmacy, China Dr Ko-Chung Lin,CEO, PharmaEssentia, Taiwan Dr Carl A J Firth, Chief Executive Officer, Aslan Pharmaceuticals, Singapore Sally Sha, Director Business Development, Tigermed, China Dr Pawel Suwinski,Healthcare & Personal Genomics Specialist, Malaysian Genomics Research Centre, Malaysia Dr Jasmine Cui, CSO, Bioduro, China Dr Ying Fei Wei, Consultant, Shenyang Sunshine Pharmaceuticals 3SBio Jonathan Wang, Partner, Legend Capital, China Xian-Ping Lu, CEO & Chief Scientific Officer, Shenzhen Chipscreen Biosciences, China Schedule: “Is China Ready to Lead in Global Drug Innovation and Development?” Navigating the Regulatory Landscape in Key Asian Countries: R&D Efforts that Translate to Approvals The Role of Asia in Drug Development Investment Appetite for Pharma R&D Innovation in Asia PHARMA IDOL: INNOVATION SHOWCASE Future of Scientific Innovation in China in the CXO Panel Discussion Emerging Business Models in Pharma R&D and Drug Development and Partnering Strategies that Work in Asia What is the Role of Academia in Drug Discovery and Development Resolve Clinical Development Future Opportunities in Biosimilars and Biobetters |
